Overview

Intensified Azacitidine in High Risk Myelodysplastic Syndrome (MDS)

Status:
Completed
Trial end date:
2015-11-01
Target enrollment:
Participant gender:
Summary
A phase I/II study of the efficacy and safety of an intensified schedule of Azacitidine (Vidaza®) in intermediate-2 and high risk MDS patients.
Phase:
Phase 1/Phase 2
Details
Lead Sponsor:
Groupe Francophone des Myelodysplasies
Treatments:
Azacitidine